

Stockholm, Sweden

August 1, 2018

## **Calliditas Therapeutics selected to present at the 25<sup>th</sup> Annual NewsMakers in the Biotech Industry**

**Calliditas Therapeutics AB (publ) today announced that the company has been selected to present at the prestigious investment conference NewsMakers in the Biotech Industry, arranged by BioCentury in New York on September 7, 2018.**

Only 48 companies are hand-picked by BioCentury and will have the opportunity to present their stories in a turf-neutral forum to the most active institutional investors in biotech today. In 2017, the presenting companies had exclusive access to an audience that controlled more than \$500 billion in equity investments.

“We are very proud to have been selected to present at NewsMakers in the Biotech Industry. BioCentury is an important forum for life science investors globally, and its annual conference in New York gives us a great opportunity to convey our story to international investors”, said Renée Aguiar-Lucander, CEO of Calliditas Therapeutics.

*The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CEST on August 1, 2018.*

**For further information, please contact:**

Mikael Widell, Head of Communications

Email: [mikael.widell@calliditas.com](mailto:mikael.widell@calliditas.com)

Telephone: +46 703 11 99 60

**About Calliditas**

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit [www.calliditas.com](http://www.calliditas.com) for further information.